Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carasent AB (publ)'s EBIT per Share for the
three
months ended in Jun. 2026 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.02.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Carasent AB (publ)'s EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Carasent AB (publ) was 58.90% per year. The lowest was -19.80% per year. And the median was 24.20% per year.
FRA:E0C's 3-Year EBIT Growth Rate is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 12 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Carasent AB (publ) (FRA:E0C) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Carasent AB (publ) EBIT per Share Related Terms
Carasent AB (publ) EBIT per Share Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carasent AB (publ) (FRA:E0C) has a EBIT per Share of €0.02 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Carasent AB (publ) and its competitors. According to the industry distribution chart, Carasent AB (publ) ranks #999999 out of 525 companies in the Healthcare Providers & Services industry.
Is Carasent AB (publ)'s EBIT per Share too high?
Carasent AB (publ)'s current EBIT per Share is €0.02. Based on the distribution chart, Carasent AB (publ) ranks #999999 out of 525 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #999999 out of 525 companies for EBIT per Share. This places Carasent AB (publ) in the lower half of its industry. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current EBIT per Share is €0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Based on GuruFocus' analysis, Carasent AB (publ) (FRA:E0C) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.46, compared to a current price of €2.06 — trading 16.5% below its estimated fair value. The current EBIT per Share is €0.02. Carasent AB (publ)'s overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Carasent AB (publ) (FRA:E0C), the current EBIT per Share is €0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (FRA:E0C) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of €2.06 is trading 16.5% below its estimated GF Value™ of €2.46.
GuruFocus considers Carasent AB (publ) to be Modestly Undervalued.
Key valuation signals for FRA:E0C:
EBIT per Share: €0.02
GF Value™: €2.46 vs. price of €2.06 (16.5% below fair value)
No single metric tells the full story. See the FRA:E0C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
79GF Score
Get the complete analysis for FRA:E0C
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E0C has been successfully added to your 
